相关实验视频

Updated: Jan 11, 2026

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

在饮食诱导的肥胖小鼠中,Achyranthes bidentata多糖体对抗肥胖的作用

Sheng-Nan Li^1,2, Wen-Kui Zhang^1,2, Yi-Man Liu¹

¹School of Medicine Henan Polytechnic University Jiaozuo Henan China.

Food science & nutrition

|November 17, 2025

概括

阿奇兰特斯双多糖 (ABPs) 通过减少炎症,改善胰岛素耐药性和恢复小鼠肠道微生物群平衡来打击肥胖. 这些生物活性化合物还可以缓解肝损伤,调节新陈代谢.

科学领域:

药理学药理学是指药理学的学科.
营养科学营养科学
微生物学微生物学

背景情况:

肥胖症的特点是慢性炎症,胰岛素抵抗和肠道失调.
阿奇兰二多糖 (ABP) 是具有潜在治疗性能的生物活性化合物.
传统的中国医学利用阿奇兰为各种健康益处.

研究的目的:

为了研究Achyranthes bidentata多糖 (ABP) 的抗肥胖作用.
评估ABP对饮食诱导的肥胖小鼠代谢参数,炎症和肠道微生物群的影响.

主要方法:

从Achyranthes bidentata水提取物中分离出多糖.
用高脂肪饮食 (HFD) 养的小鼠用ABPs进行了治疗.
进行了基因表达分析 (GLUT1,PGC-1α,PPARα,PPARγ,C/EBPα,SOX4).
分析了肠道微生物群的组成和短链脂肪酸 (SCFA) 的水平.

主要成果:

在HFD养的小鼠中,ABP治疗减轻了肥胖,胰岛素抵抗和肝损伤.
ABP通过调节GLUT1和PGC-1α表达来调节葡萄糖代谢.
ABP改变了肠道微生物群,减少了Firmicutes:Bacteroidota比率和特定的细菌丰度,同时增加了SCFA,特别是酸.

结论:

阿奇兰二多糖 (ABP) 显示出显著的抗肥胖作用.
ABP改善肝脏新陈代谢,减少全身炎症.
ABP改善了肠道微生物群的失调,并恢复了SCFA水平,为肥胖提供了潜在的治疗策略.

关键词:

亚基兰特斯二达塔 (Achyranthes bidentata) 是一个长的植物.我们的肠道微生物群.肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖聚糖类是一种多糖类.

更多相关视频

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

Palatable Western-style Cafeteria Diet as a Reliable Method for Modeling Diet-induced Obesity in Rodents

Palatable Western-style Cafeteria Diet as a Reliable Method for Modeling Diet-induced Obesity in Rodents

Published on: November 1, 2019

相关概念视频

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...